ES2005166A6 - Un procedimiento para la preparacion de un sistema adyuvante constituido por un antigeno y un adyuvante inmulogico. - Google Patents

Un procedimiento para la preparacion de un sistema adyuvante constituido por un antigeno y un adyuvante inmulogico.

Info

Publication number
ES2005166A6
ES2005166A6 ES8701112A ES8701112A ES2005166A6 ES 2005166 A6 ES2005166 A6 ES 2005166A6 ES 8701112 A ES8701112 A ES 8701112A ES 8701112 A ES8701112 A ES 8701112A ES 2005166 A6 ES2005166 A6 ES 2005166A6
Authority
ES
Spain
Prior art keywords
immunological
lipid emulsion
adjuvant
emulsion adjuvant
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8701112A
Other languages
English (en)
Spanish (es)
Inventor
John L Cantrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of ES2005166A6 publication Critical patent/ES2005166A6/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES8701112A 1986-04-15 1987-04-15 Un procedimiento para la preparacion de un sistema adyuvante constituido por un antigeno y un adyuvante inmulogico. Expired ES2005166A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/852,120 US4806352A (en) 1986-04-15 1986-04-15 Immunological lipid emulsion adjuvant

Publications (1)

Publication Number Publication Date
ES2005166A6 true ES2005166A6 (es) 1989-03-01

Family

ID=25312542

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8701112A Expired ES2005166A6 (es) 1986-04-15 1987-04-15 Un procedimiento para la preparacion de un sistema adyuvante constituido por un antigeno y un adyuvante inmulogico.

Country Status (9)

Country Link
US (1) US4806352A (OSRAM)
JP (1) JPS6310736A (OSRAM)
AU (1) AU574014B2 (OSRAM)
CA (1) CA1300503C (OSRAM)
DE (1) DE3712767A1 (OSRAM)
ES (1) ES2005166A6 (OSRAM)
FR (2) FR2598622B1 (OSRAM)
GB (1) GB2189141B (OSRAM)
IT (1) IT1205819B (OSRAM)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
JPH0832637B2 (ja) * 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
DE3601136A1 (de) * 1986-01-16 1987-07-23 Max Planck Gesellschaft Hemmstoffe der reversen transkriptase fuer prophylaxe und therapie von retrovirus-infektionen in saeugetieren
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6054438A (en) * 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
US5466714A (en) * 1987-12-31 1995-11-14 Research Foundation For Mental Health Hygiene, Inc. Spermicidal and cytocidal fatty acid compositions
US5434182A (en) * 1987-12-31 1995-07-18 Isaacs; Charles E. Antibacterial fatty acid compositions
US4997851A (en) * 1987-12-31 1991-03-05 Isaacs Charles E Antiviral and antibacterial activity of fatty acids and monoglycerides
EP0324455A3 (en) * 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
WO1990003183A1 (en) * 1988-09-23 1990-04-05 University Of Southern California Immunotherapy vaccine for melanoma tumors
FI902821A7 (fi) * 1989-06-12 1990-12-13 Res Foundation For Mental Hygiene Infektion leviämisen vähentäminen verenkäsittelylaitteistolla
DE4007315A1 (de) * 1990-03-08 1991-09-12 Behringwerke Ag Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
DE69230372T2 (de) 1991-03-19 2000-06-15 Cytrx Corp., Norcross Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität
IE921212A1 (en) * 1991-04-19 1992-10-21 Affinity Biotech Inc Convertible microemulsion formulations
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
AU685443B2 (en) * 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
ATE246513T1 (de) * 1993-05-27 2003-08-15 Entremed Inc Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
ATE386506T1 (de) * 1995-10-17 2008-03-15 Jagotec Ag Verabreichung unlöslicher arzneistoffe
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US5849307A (en) * 1997-03-26 1998-12-15 The Picower Institute For Medical Research Vaccine adjuvant
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
ES2201673T3 (es) * 1998-02-11 2004-03-16 Rtp Pharma Corporation Combinacion de esteroides y acidos grasos poiinsaturados para el tratamiento de estados inflamatorios.
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
CA2333648C (en) 1998-05-29 2008-10-21 Rtp Pharma Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
SK288117B6 (sk) 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
KR20060134225A (ko) 1999-04-09 2006-12-27 파마시아 앤드 업존 캄파니 엘엘씨 항균성 백신 조성물
JP2003509453A (ja) * 1999-09-21 2003-03-11 アールティーピー・ファーマ・インコーポレーテッド 生物学的に活性な物質の、表面改質された粒状組成物
BR0109322A (pt) 2000-03-17 2002-12-10 Upjohn Co Materiais e métodos de vacina de salmonella
US6764823B2 (en) 2000-04-06 2004-07-20 Pharmacia & Upjohn Company Antimicrobial methods and materials
NZ522239A (en) 2000-04-20 2004-03-26 Skyepharma Canada Inc Improved water-insoluble drug particle process
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
JP4969761B2 (ja) 2000-08-31 2012-07-04 オバン・エナジー・リミテッド 所望粒度を持つ固体基材の小粒子および第一材料の小粒状物を含む相乗作用性混合物を製造する方法
TWI354568B (en) * 2000-09-20 2011-12-21 Jagotec Ag Insoluble drug particle compositions with improved
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
ES2284646T3 (es) * 2001-02-22 2007-11-16 Jagotec Ag Combinaciones de estatina-fibrato con efectos secundarios en ayunas-alimentado reducidos.
FR2824279B1 (fr) * 2001-05-04 2004-05-28 Seppic Sa Emulsion e/h concentree
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
FR2824269B1 (fr) * 2001-09-03 2012-03-02 Seppic Sa Composition adjuvante constituee de 1% a 15% de tensioactifs a hlb global compris entre 5 et 8 et de 85% a 99% de corps gras
EP1594524B1 (en) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
WO2007109810A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
US8173657B2 (en) * 2006-03-23 2012-05-08 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
WO2007109812A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
WO2009039628A1 (en) 2007-09-27 2009-04-02 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
US20110070298A1 (en) 2008-06-05 2011-03-24 Immunovaccine Technologies Inc. Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance
SG172060A1 (en) 2008-12-09 2011-07-28 Gilead Sciences Inc Modulators of toll-like receptors
US8464405B2 (en) 2010-01-29 2013-06-18 Kabushiki Kaisha Mikimoto Jewelry clasp
KR102085465B1 (ko) 2010-05-14 2020-03-05 박스알타 인코퍼레이티드 키메라 ｏｓｐａ 유전자, 단백질 및 이의 사용 방법
WO2012010290A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
CN103347536A (zh) 2010-12-08 2013-10-09 尼奥瓦克斯公司 强灭活且仍高免疫原性的疫苗及其制备方法
EP2508197A1 (en) 2011-04-07 2012-10-10 Neovacs Method for treating IFNalpha related conditions
CA2832260C (en) 2011-04-07 2021-06-22 Neovacs Method for treating ifnalpha related conditions
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
EP3682897A1 (en) 2012-07-27 2020-07-22 Baxalta GmbH Compositions comprising chimeric ospa molecules and methods of use thereof
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
US11725044B2 (en) 2014-10-15 2023-08-15 Xenothera Method for producing polyclonal antibodies with improved complement-dependent cytotoxicity
US20210228713A1 (en) 2018-06-04 2021-07-29 Apros Therapeutics, Inc. Tlr7 peptide conjugates
KR20210027381A (ko) 2018-07-02 2021-03-10 아유비스 리서치, 인코포레이티드 신규 면역조절 소분자
EP3922255A1 (en) 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
GB202009411D0 (en) 2020-06-19 2020-08-05 Prokarium Ltd Autotransporter systems
CN112807426A (zh) * 2021-01-26 2021-05-18 郭志文 一种基于动物疫苗的聚合物佐剂、制备方法及其应用
EP4124342A1 (en) 2021-07-28 2023-02-01 Prokarium Limited Cancer therapy with live attenuated bacteria
US20240424086A1 (en) 2021-09-07 2024-12-26 Universite De Tours Coronavirus fusion protein
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit
WO2025068401A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 15 variant
WO2025068413A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 18 variants
WO2025109155A1 (en) 2023-11-24 2025-05-30 Prokarium Limited Interleukin variant
WO2025224251A1 (en) 2024-04-24 2025-10-30 Prokarium Limited Modified microorganisms
GB202405780D0 (en) 2024-04-24 2024-06-05 Prokarium Ltd Vacuole escape

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1163470A (en) * 1967-11-13 1969-09-04 Cecil Arthur Clark Improvements in or relating to Adjuvant Vaccines
CA943459A (en) * 1968-12-16 1974-03-12 Abbott Laboratories Chemically modified endotoxin immunizing agent
FR2160326B1 (OSRAM) * 1971-11-19 1975-02-07 Anvar
US4185090A (en) * 1972-02-02 1980-01-22 Abbott Laboratories Chemically modified endotoxin immunizing agent
GB1506563A (en) * 1974-04-25 1978-04-05 Williams J Immunosuppressive agents
FR2313078A1 (fr) * 1975-02-07 1976-12-31 Anvar Composition a base d'huile vegetale metabolisable et d'eau, utilisable notamment pour la constitution de preparations adjuvantes, ces preparations adjuvantes et leur procede d'obtention
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
US4307229A (en) * 1979-11-07 1981-12-22 Avraham Liav 6,6'-Diesters of trehalose and process for the synthesis thereof
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
CA1225592A (en) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
JPH077201B2 (ja) * 1985-10-19 1995-01-30 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料の処理方法

Also Published As

Publication number Publication date
JPS6310736A (ja) 1988-01-18
FR2598622A1 (fr) 1987-11-20
DE3712767C2 (OSRAM) 1991-06-27
IT1205819B (it) 1989-03-31
DE3712767A1 (de) 1987-10-22
US4806352A (en) 1989-02-21
AU574014B2 (en) 1988-06-23
FR2596990A1 (fr) 1987-10-16
FR2596990B1 (fr) 1990-12-07
GB8709023D0 (en) 1987-05-20
AU7156687A (en) 1987-10-22
FR2598622B1 (fr) 1990-05-11
GB2189141A (en) 1987-10-21
JPH041728B2 (OSRAM) 1992-01-14
IT8747855A0 (it) 1987-04-15
CA1300503C (en) 1992-05-12
GB2189141B (en) 1990-07-25

Similar Documents

Publication Publication Date Title
ES2005166A6 (es) Un procedimiento para la preparacion de un sistema adyuvante constituido por un antigeno y un adyuvante inmulogico.
AU7176087A (en) Vaccine formulation
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
CA2086094A1 (en) Vaccine compositions containing liposomes
IL88076A (en) Fat emulsions as drug carriers
AU2548184A (en) Mucoid exopolysaccharide vaccine against pseudomonas aeruginosa
NZ209635A (en) Pharmaceutical composition containing extract from microorganism and detoxified endotoxin
EP0694309A3 (en) Vaccine, antigens and antibodies containing compound for inhibiting and preventing induced staphylococcus infection
ES2002740A6 (es) Emulsion aceite-en-agua, especialmente preparaciones topicas y cosmeticas.
EP0363110A3 (en) High ph extraction composition and its use to determine a chlamydial, gonococcal or herpes antigen
GB1242518A (en) Defoaming emulsion
AU6703086A (en) An oil-in-water pesticidal emulsion
EP0315153A3 (en) Vaccine adjuvant
EP0285391A3 (en) Organopolysiloxane emulsion and method for the preparation thereof
EP0283840A3 (en) Mycoplasma hyopneumoniae antigen and uses therefor
AU3594089A (en) Poultry mycoplasma antigens and recombinant vectors containing the gene as well as diagnostics and vaccines utilizing the same
AU7712187A (en) Coccidiosis vaccine
DE3773140D1 (de) Hydrodynamisches lager.
IT8619808A0 (it) Apparecchiatura per l'isolamento di vibrazioni in particolare vibrazioni da terremoto.
ES2005167A6 (es) Un procedimiento para la preparacion de una mezcla de un antigeno polisacarido y un adyuvante inmunologico.
EP0367302A3 (en) Process for semi-synthesis of human insulin, water-soluble cross-linked achromobacter protease i for use therein and a process for preparing the same
OA09500A (en) Excretory/secretory antigens of tapeworm (cysticercus cellulosae) for use in immunodiagnosis and vaccine preparation.
McVeigh et al. Lipopolysaccharide is a major protective antigen in the polyvalent Pseudomonas vaccine PEV.
Jackson The SLOOP Manual
Wallace An Unpublished Michelangelo Document

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20070416